Exelixis, Inc.
EX9.DE
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.08B
Close$
$53.68
66.3% upside
Current Fair Value
66.3% upsideUndervalued by 66.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.08 Billion |
|---|---|
| Enterprise Value | $15.96 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.88 |
| Beta | 0.54 |
| Outstanding Shares | 258,329,000 |
Return
| Return on Equity | 33.42% |
|---|---|
| Return on Assets | 24.70% |
| Return on Invested Capital | 35.94% |
Valuation & Multiples
| P/E Ratio | 18.19 |
|---|---|
| PEG | 123.64 |
| Price to Sales | 4.61 |
| Price to Book Ratio | 4.61 |
| Enterprise Value to Revenue | 8.69 |
| Enterprise Value to EBIT | 20.82 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.75
Average shareholder expectationRevenue Estimate
$557.24 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Exelixis Inc
1,077 employees
CEO: Michael Morrissey Exelixis, Inc. is a biotechnology firm primarily focused on addressing oncology, dedicated to the discovery, development, and commercialization of innovative therapeutic agents for cancer treatment within the United States. The company m...